Advertisement
Advertisement
U.S. markets close in 1 hour 26 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Kintara Therapeutics, Inc. (KTRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8900-0.0466 (-4.98%)
As of 2:32PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.9366
Open0.9322
Bid0.8900 x 4000
Ask0.8925 x 1000
Day's Range0.8708 - 0.9322
52 Week Range0.7400 - 3.3500
Volume1,786,478
Avg. Volume1,548,769
Market Cap38.426M
Beta (5Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)-1.6030
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KTRA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kintara Therapeutics, Inc.
    Market Digest: CNI, NDAQ, BK, GILD, ISRG, MKTX, NFLX, SWXAs Earnings Roll in, the Economy Rolls on
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Zacks Small Cap Research

    KTRA: FY21 Financial Results

    By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT Fiscal Year 2021 Operational and Financial Results Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced fiscal year 2021 financial and operational results in a September 29 th press release and filed its 10-K with the SEC. Highlights for the fourth quarter ended June 30, 2021 and to-date include: ➢ GCAR GBM AGILE trial launch

  • PR Newswire

    Kintara Therapeutics to Present at the LD Micro Main Event Conference

    Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces today that its Chief Executive Officer, Saiid Zarrabian, will present a corporate overview at the 14th Annual LD Micro Main Event Conference which is being held at the Luxe Sunset Bel-Air in Los Angeles from October 12 – 14, 2021.

  • PR Newswire

    Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate Update

    https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2021 and provided a corporate update.

Advertisement
Advertisement